Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

Bodaghi, Bahram; Gendron, G.; Wechsler, B.; Terrada, C.; Cassoux, Nathalie; Huong, D. Lê Thi; Lemaitre, Claire; Fradeau, Christine; LeHoang, Phuc; Piette, Jean‐Charles

doi:10.1136/bjo.2006.101550

Cited by 174 publications

(93 citation statements)

References 34 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One or two doses of AIN457 significantly reduced the disease activity compared to the placebo-treated group (for psoriasis and RA) or had effects comparable to those of historical control subjects for chronic noninfectious uveitis treated with a biologic therapy (30).…”

Section: Discussionmentioning

confidence: 99%

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

et al. 2010

View full text Add to dashboard Cite

Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T H 17) subset of T H cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental autoimmune uveitis. To determine whether IL-17A mediates human inflammatory diseases, we investigated the efficacy and safety of AIN457, a human antibody to IL-17A, in patients with psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis. Patients with chronic plaque-type psoriasis (n = 36), rheumatoid arthritis (n = 52), or chronic noninfectious uveitis (n = 16) were enrolled in clinical trials to evaluate the effects of neutralizing IL-17A by AIN457 at doses of 3 to 10 mg/kg, given intravenously. We evaluated efficacy by measuring the psoriasis area and severity index (PASI), the American College of Rheumatology 20% response (ACR20) for rheumatoid arthritis, or the number of responders for uveitis, as defined by either vision improvement or reduction in ocular inflammation or corticosteroid dose. AIN457 treatment induced clinically relevant responses of variable magnitude in patients suffering from each of these diverse immune-mediated diseases. Variable response rates may be due to heterogeneity in small patient populations, differential pathogenic roles of IL-17A in these diseases, and the different involvement or activation of IL-17A-producing cells. The rates of adverse events, including infections, were similar in the AIN457 and placebo groups. These results support a role for IL-17A in the pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, and noninfectious uveitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Open-label studies [Boyvat et al 2000;O'Duffy et al 1998;Georgiou et al 1998;Azizlerli et al 1996;Alpsoy et al 1994] Eye involvement Uncontrolled prospective study [Kotter et al 2003] Retrospective studies [Onal et al 2011;Sobaci et al 2010;Deuter et al 2010;Bodaghi et al 2007;Tugal-Tutkun et al 2006;Deuter et al 2004;Krause et al 2003;Calguneri et al 2003;Hamuryudan et al 2002;Wechsler et al 2000;Yalcindag and Uzun, 2012] Systematic review [Kotter et al 2004a] Mucocutaneous disease and arthritis Uncontrolled prospective study [Kotter et al 2004b] Systematic review [Kotter et al 2004a] Neuro-Behçet Case reports [Nichols et al 2001;Kuemmerle-Deschner et al 2008;…”

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

114

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

“…86 For BD, and also in other forms of non-infectious uveitis, IFN-a (which are delivered as monotherapy or in conjunction with corticosteroids) have also been successfully utilised, with both a small RCT and long-term prospective and retrospective studies demonstrating that almost 60% of patients can achieve remission and discontinue treatment. [87][88][89][90][91][92] Generating potential local treatments may circumvent many of the systemic adverse events of biologic therapy and also potentially reduce cost. Local anti-TNF inhibition is a new and promising therapeutic direction where pre-clinical studies of the TNF inhibitior ESBA105 suggest good intravitreal and neuroretinal bioavailability.…”

Section: Recent and Future Treatmentsmentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.

show abstract

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

Cited by 174 publications

References 34 publications

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Update on the therapy of Behçet disease

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Contact Info

Product

Resources

About